IFF attributes Scent's rebound to Fragrance Ingredients momentum, with Fine Fragrance stabilizing amid volatility and Consumer Fragrance propelled by an R&D-led recovery and go-to-market rebuild. The company expects a mid-single-digit 2H for Fine Fragrance and a low single-digit pace for Consumer Fragrance, supported by a strengthened R&D pipeline targeting 2027.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
While your question is specifically about “Scent,” IFF’s Scent segment results in these excerpts are heavily supported by Fragrance Ingredients momentum—particularly in the second quarter and as a bridge into 2H. In Q2, Fragrance Ingredients grew “north of 20%”, and the company attributes part of the gain to easy comparisons (comparing against a year-ago period described as down “10% or more”) and part to strategic execution: leveraging the synthetics portfolio to capture more sales amid macro/supply-chain conditions including “higher Brent crude prices.” 1 Management also states that as conditions settle, Fragrance Ingredients growth is expected to shift back toward higher value-added ingredients vs. traditional synthetics, and that this normalization is included in the second-half forecast. 1
Additionally, management expects Fragrance Ingredients “to normalize on a go-forward basis” and says it will be slightly under pressure YoY in calibration terms. 2
Implication for recovery: Scent’s recovery is not only an end-demand story; it’s supported by product/portfolio execution in Fragrance Ingredients, with management explicitly forecasting normalization (a move from an “exceptional” comp/portfolio mix toward more typical growth and mix). 12
Fine Fragrance recovery is described as being helped by management of geopolitical volatility risk and pacing of quarter-by-quarter effects. The company says it managed the challenges in the Middle East and that while growth had been expected “down in Fine Fragrance mid-single digits,” it finished up slightly positive. 1
For 2H, management frames the trajectory as:
Implication for recovery: The recovery driver for Fine Fragrance is operational execution under external uncertainty (Middle East) plus expected improvement later in the year as comps and conditions evolve. 1
On Consumer Fragrance, the excerpt ties recovery to a multi-part strategic initiative:
In terms of evolution, Consumer Fragrance is expected to sit in the low single-digit range on a go-forward basis after a strong Q2: Q2 reportedly delivered high single-digit growth, and management expects normalization “on a go-forward basis to kind of a low single-digit number.” 2
Implication for recovery: Consumer Fragrance recovery is framed as an internal capability and commercial execution rebound (compounds + R&D + customer GTM), followed by stabilization/normalization in growth rate. 2
The company explicitly describes the state of its R&D function and the progress made over the turnaround period:
Management also frames confidence for the future: while not satisfied, it is “making really good progress… addressing our gaps” and they are “very optimistic about the future of Scent.” 3
Implication for recovery: The driver is not only near-term market effects; it’s the rebuilding of the R&D engine and pipeline quality that supports competitive positioning beyond the immediate “recovery year.” 3
Management’s direct guidance for Scent’s second half, split by Fine vs. Consumer:
So the expected shape is Q3 dip/softness → Q4 recovery, with the full 2H landing in mid-single digits overall. 21
For Consumer Fragrance:
So Consumer Fragrance is expected to decelerate from the strong Q2 to a low single-digit run-rate for the remainder of 2H. 2
The excerpts do not provide a line-item “R&D roadmap” with specific budgets or project counts, but they do provide a clear plan logic and the components management says will support 2027:
Management explicitly states the recovery in Consumer Fragrance includes “rebuild the R&D capability” along with go-to-market and compounds execution to drive market share gains. 2
This implies a continuing investment stance, not a one-quarter fix, because the same excerpt connects the R&D work to improving competitive position “as we go into next year and the year after.” 2
IFF attributes progress to tangible pipeline depth:
This is the operational foundation for sustaining product innovation relevance into 2027, not merely stabilizing current offerings. 3
Management underscores that while progress is strong, it is “not satisfied” and that it has “more to do” by explicitly saying it is strengthening strengths and addressing gaps. 3
Interpretation consistent with the excerpt: R&D is positioned as an ongoing transformation capability—supporting market share and competitive positioning beyond 2026—rather than a completed initiative. 3
R&D support in Scent into 2027 is also implicitly linked to the Fragrance Ingredients strategy: a shift to “higher-value natural products” that management says is “underway,” but “will take a little bit more time,” specifically not fully in the second half of 2026; instead it’s expected “as we go into next year and the year after” that they will have a “really strong competitive position.” 2
This is consistent with a longer-horizon transformation that R&D must support (natural product development + systems integration), even if the excerpt does not explicitly label every step as “R&D.” 2
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent recovery is anchored in a rebuilt R&D engine and stronger go-to-market execution, with near-term tailwinds from fragrance ingredients. 2H 2026 guidance shows Fine Fragrance accelerating into Q4 while Consumer Fragrance normalizes to low single-digit growth, as Middle East volatility subsides. The 2027 plan focuses on a robust pipeline and higher-value ingredient mix to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to a rebuilt R&D engine, stronger perfumers, and improved go-to-market execution, while guiding a softer Q3 and stronger Q4 for Fine Fragrance and a normalized low single-digit path for Consumer Fragrance in 2H. The company also emphasizes an expanded R&D program—molecules, delivery systems, and higher-value ingredients—to sustain growth into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a strengthened R&D pipeline and a revamped go-to-market strategy, with Consumer Fragrance poised for market-share gains while Fine Fragrance navigates regional volatility. The company frames 2027 as a natural extension of its enhanced R&D capabilities, with a shift toward higher-value, natural ingredients and sustained innovation to support growth in the second half and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi‑driver path to Scent recovery, led by Fragrance Ingredients momentum, improved Consumer and Fine Fragrance execution, and an R&D overhaul aimed at 2027. In 2H, Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes from a high single-digit Q2 growth to a low single-digit trajectory, supported by a revamped product pipeline and go‑to‑market strategy.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, stabilization in Fine Fragrance, and a rebuilt Consumer Fragrance engine anchored by R&D and go-to-market improvements. The 2H 2026 path points to a Q3 softness followed by a Q4 rebound, with a longer runway toward 2027 supported by an 8–9% R&D intensity and a strengthened innovation pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by strong Fragrance Ingredients growth and a rebuilt R&D engine, with a mid-to-long-term plan to enhance market position into 2027. In H2, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance trends toward low single-digit growth as R&D and go-to-market initiatives support share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to robust Fragrance Ingredients growth and an improved R&D pipeline, with plans to support 2027. Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes to a low single-digit growth profile.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent rebound in Q2 2026 rests on normalization of Fragrance Ingredients, resilient Fine Fragrance execution amid Middle East volatility, and a rebuild of R&D and go-to-market for Consumer Fragrance. Management signals a mid‑single‑digit H2 for Fine Fragrance and low single-digit growth for Consumer Fragrance, underpinned by an improved R&D pipeline and a long-term push into 2027 with higher-value ingredients and delivery systems.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 results underscore a resilient Scent recovery driven by double-digit Fragrance Ingredients growth and solid Consumer Fragrance momentum, with a rebuilt R&D pipeline set to support growth into 2027. In the second half, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace as R&D and go-to-market improvements support market share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management attributes Scent's rebound to a rebuilt R&D engine and stronger go-to-market execution, with 2H expected to show mid-single-digit growth for Fine Fragrance and low-single-digit gains for Consumer Fragrance, while Fragrance Ingredients normalizes. The plan emphasizes sustained R&D investment around 8-9% of sales to support a pipeline of molecules, delivery systems, and innovative products through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, a cautious but improving Fine Fragrance trajectory through Middle East volatility, and a Consumer Fragrance rebound driven by rebuilt R&D and go-to-market capabilities aimed at market-share gains. The plan emphasizes a multi-year R&D rebuild, a deep pipeline of molecules and delivery systems, and an innovation-first path to 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi-faceted Scent recovery driven by stabilizing Fine Fragrance demand, normalization of Consumer Fragrance through revamped R&D and go-to-market execution, and a shift toward higher-value Fragrance Ingredients. The firm also details a robust 2027 R&D plan designed to sustain competitive advantage with an strengthened pipeline, leading-edge perfumers, and sustained reinvestment in innovation, aligned to long-term growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi